Product Details
| Product Name:
CCT007093 |
CAS No.:
176957-55-4 |
| Purity:
99.88% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | CCT007093 |
| Description | CCT007093 is an effective PPM1D (WIP1) inhibitor (IC50: 8.4 μM). |
| Cell Research | Cells are transfected with a pSUPER plasmid and an additional plasmid expressing the blasticidin resistance gene (pEFBsd) in a molar ratio of 10:1. Cells are plated in 10?cm plates 24?h after transfection. Blasticidin selection (5?μg/ml) is initiated 48?h post-transfection and replenished every 3 days. Colonies are fixed in methanol and stained with crystal violet after 14 days. Colonies are quantified on a Colcount and the surviving fraction (SF) determined.(Only for Reference) |
| Kinase Assay | In vitro phosphatase assay: Recombinant PPM1D (20-50?pmol) is diluted in Tris buffer (50?mM, pH 8), NaCl (100?mM), β-mercaptoethanol (1?mM) or DTT (1?mM) and treated with MnCl2 (0, 1, 10 and 20?mM) or MgCl2 (0 and 40?mM). Where appropriate, inhibitors of PPM1D (10-50?μM) are added and the assay mix incubated for 30?min at room temperature. Recombinant phospho-P38 (200?pmol) is then added and the mixture incubated at 37°C for 1?h. The reaction is quenched by the addition of excess ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulphate-sample loading buffer and boiling for 5?min at 95°C followed by gel electrophoresis and western blotting. |
| In vivo | CCT007093, when used in combination with Paclitaxel, synergistically inhibits four Paclitaxel-resistant triple-negative breast cancer cell lines. CCT007093 selectively exhibits significant inhibition on human tumor cell lines over-expressing PPM1D (MCF-7, KPL-1, and MCF-3B). By activating p38 kinase activity, CCT007093 induces cell death. It selectively promotes apoptosis in breast cancer cells and ectopically expressed Wip1 in keratinocytes, while reducing UV-mediated apoptotic responses in Wip1-deficient naked cells and a skin keratinocyte model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 1.38 mg/mL (5.07 mM), Sonication is recommended.
|
| Keywords | PPM1D | Phosphatase | Inhibitor | inhibit | CCT-007093 | CCT007093 | CCT 007093 | Autophagy | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Glycometabolism Compound Library | Bioactive Compound Library | Autophagy Compound Library | Multi-Target Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Phosphatase Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$9.80
|
VIP7Y
|
Career Henan Chemical Co
|
2020-01-14 |
United States